Emerging blood-based biomarkers for Alzheimer disease

REFERENCES

1. ↵
   1. Alzheimer’s Association

   . 2020 Alzheimer’s disease facts and figures. Alzheimers Dement 2020 Mar 10. doi:10.1002/alz.12068

   OpenUrlCrossRef
2. ↵
   1. Gallardo G,
   2. Holtzman DM

   . Amyloid-ß and tau at the crossroads of Alzheimer’s disease. Adv Exp Med Biol 2019; 1184:187203. doi:10.1007/978-981-32-9358-8_16

   OpenUrlCrossRef
3. ↵
   1. Cohen AD,
   2. Landau SM,
   3. Snitz BE,
   4. Klunk WE,
   5. Blennow K,
   6. Zetterberg H

   . Fluid and PET biomarkers for amyloid pathology in Alzheimer’s disease. Mol Cell Neurosci 2019; 97:3–17. doi:10.1016/j.mcn.2018.12.004

   OpenUrlCrossRef
4. ↵
   1. Schöll M,
   2. Maass A,
   3. Mattsson N, et al

   . Biomarkers for tau pathology. Mol Cell Neurosci 2019; 97:18–33. doi:10.1016/j.mcn.2018.12.001

   OpenUrlCrossRef
5. ↵
   1. Boyle PA,
   2. Yu L,
   3. Leurgans SE, et al

   . Attributable risk of Alzheimer’s dementia attributed to age-related neuropathologies. Ann Neurol 2019;85(1):114–124. doi:10.1002/ana.25380

   OpenUrlCrossRef
6. ↵
   1. Olsson B,
   2. Lautner R,
   3. Andreasson U, et al

   . CSF and blood biomarkers for the diagnosis of Alzheimer’s disease: a systematic review and meta-analysis. Lancet Neurol 2016;15(7):673–684. doi:10.1016/S1474-4422(16)00070-3

   OpenUrlCrossRefPubMed
7. ↵
   1. Zetterberg H,
   2. Mörtberg E,
   3. Song L, et al

   . Hypoxia due to cardiac arrest induces a time-dependent increase in serum amyloid ß levels in humans. PloS One 2011; 6(12):e28263. doi:10.1371/journal.pone.0028263

   OpenUrlCrossRefPubMed
8. 1. Janelidze S,
   2. Stomrud E,
   3. Palmqvist S, et al

   . Plasma ß-amyloid in Alzheimer’s disease and vascular disease. Sci Rep 2016; 6:26801. doi:10.1038/srep26801

   OpenUrlCrossRefPubMed
9. 1. Verberk IMW,
   2. Slot RE,
   3. Verfaillie SCJ, et al

   . Plasma amyloid as prescreener for the earliest Alzheimer pathological changes. Ann Neurol 2018;84(5):648–658. doi:10.1002/ana.25334

   OpenUrlCrossRef
10. 1. Nakamura A,
    2. Kaneko N,
    3. Villemagne VL, et al

    . High performance plasma amyloid-ß biomarkers for Alzheimer’s disease. Nature 2018;554(7691):249–254. doi:10.1038/nature25456

    OpenUrlCrossRef
11. ↵
    1. Ovod V,
    2. Ramsey KN,
    3. Mawuenyega KG, et al

    . Amyloid ß concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis. Alzheimers Dement 2017;13(8):841–849. doi:10.1016/j.jalz.2017.06.2266

    OpenUrlCrossRef
12. ↵
    1. Mielke MM,
    2. Hagen CE,
    3. Wennberg AMV, et al

    . Association of plasma total tau level with cognitive decline and risk of mild cognitive impairment or dementia in the Mayo Clinic Study on Aging. JAMA Neurol 2017;74(9):1073–1080. doi:10.1001/jamaneurol.2017.1359

    OpenUrlCrossRef
13. ↵
    1. Pase MP,
    2. Beiser AS,
    3. Himali JJ, et al

    . Assessment of plasma total tau level as a predictive biomarker for dementia and related endophenotypes. JAMA Neurol 2019;76(5):598–606. doi:10.1001/jamaneurol.2018.4666

    OpenUrlCrossRef
14. ↵
    1. Mielke MM,
    2. Hagen CE,
    3. Xu J, et al

    . Plasma phospho-tau181 increases with Alzheimer’s disease clinical severity and is associated with tau-and amyloid-positron emission tomography. Alzheimers Dement 2018;14(8):989–997. doi:10.1016/j.jalz.2018.02.013

    OpenUrlCrossRefPubMed
15. 1. Yang C-C,
    2. Chiu M-J,
    3. Chen T-F, et al

    . Assay of plasma phosphorylated tau protein (threonine 181) and total tau protein in early-stage Alzheimer’s disease. J Alzheimers Dis 2018;61(4):1323–1332. doi:10.3233/JAD-170810

    OpenUrlCrossRef
16. ↵
    1. Tatebe H,
    2. Kasai T,
    3. Ohmichi T, et al

    . Quantification of plasma phosphorylated tau to use as a biomarker for brain Alzheimer pathology: pilot case-control studies including patients with Alzheimer’s disease and Down syndrome. Mol Neurodegener 2017; 12(1):63. doi:10.1186/s13024-017-0206-8

    OpenUrlCrossRef
17. ↵
    1. Palmqvist S,
    2. Janelidze S,
    3. Quiroz YT, et al

    . Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders. JAMA 2020 Jul 28. doi:10.1001/jama.2020.12134

    OpenUrlCrossRef
18. ↵
    1. Barthélemy NR,
    2. Horie K,
    3. Sato C,
    4. Bateman RJ

    . Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer’s disease. J Exp Med 2020; 217(11):e20200861. doi:10.1084/jem.20200861

    OpenUrlCrossRef
19. ↵
    1. Carrillo MC,
    2. Blennow K,
    3. Soares H, et al

    . Global standardization measurement of cerebral spinal fluid for Alzheimer’s disease: an update from the Alzheimer’s Association Global Biomarkers Consortium. Alzheimers Dement 2013;9(2):137–140. doi:10.1016/j.jalz.2012.11.003

    OpenUrlCrossRefPubMed